Navigation Links
Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
Date:6/11/2008

LONDON, June 11 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced that it has obtained regulatory approval from the South African Medicines Control Council (MCC) to initiate a Phase II study of MRX-4 in 105 patients suffering from allergic rhinitis (AR). The two-arm, randomized, multi-dose, double-blind, placebo-controlled study includes a steroid comparator arm.

The study will evaluate the safety, tolerability, and preliminary efficacy of intranasal MRX-4 in AR patients outside of allergy season as compared with both placebo and an intranasal steroid. An experimental multi-functional anti-inflammatory drug (MFAID), MRX-4 is a non-steroidal potential treatment for AR that was shown to be safe and well tolerated in a Phase I equivalent trial completed in Israel earlier this year.

"This study will provide valuable data regarding its potential in allergic rhinitis, including efficacy, tolerability and pharmacokinetic data," said Dr. Yuval Cohen, president of Morria. "We are excited to be taking this significant step toward testing a potentially safer, more effective, and more affordable treatment option for the significant commercial opportunity in the multi-billion dollar allergic rhinitis market".

ABOUT ALLERGIC RHINITIS

Allergic rhinitis is a common condition that affects nearly 59 million people in the United States (nearly 20 percent of the population) with a market of close to $4 billion. Allergic rhinitis is characterized by inflammation of the nasal membranes accompanied by symptoms that may include sneezing, nasal congestion, nasal itching and rhinorrhea.

ABOUT MORRIA BIOPHARMACEUTICALS Plc

Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on the development of novel anti-inflammatory pharmaceuticals termed multi-functional anti-inflammatory drugs (MFAIDs). This class of drugs uniquely combine
'/>"/>

SOURCE Morria Biopharmaceuticals Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
2. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
3. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
5. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
6. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
7. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
8. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
9. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
10. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
11. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 28, 2014 China Nepstar Chain ... the "Company"), a leading retail drugstore chain in ... stores, today announced its unaudited financial results for ... Financial HighlightsFor the quarter ended June 30, 2014: ... million) compared to RMB638.8 million in the second ...
(Date:8/27/2014)... , Aug. 27, 2014 TWi Pharmaceuticals, ... approval from the United States Food and Drug ... (ANDA) for megestrol acetate 125mg/ml oral suspension, the ... is the first-to-file and under Hatch Waxman rules, ... marketing exclusivity.  TWi has completed the pre-launch preparation ...
(Date:8/27/2014)... 27, 2014 Reportbuyer.com has added ... Collaborative R&D Terms & Agreements in Pharma, ... The Collaborative R&D Terms and ... provides comprehensive understanding and unprecedented access to ... into by the worlds leading life science ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 11TWi Pharmaceuticals Receives US FDA Final Approval on Generic Megestrol Acetate 125mg/ml Oral Suspension 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 4Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 5Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 6Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 7Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 8Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 9
... Mylan Inc. (Nasdaq: MYL ) today ... final approval from the U.S. Food and Drug Administration ... Ibandronate Sodium Tablets, 150mg. This product is the generic ... treatment and prevention of osteoporosis in postmenopausal women. ...
... YORK, March 20, 2012 Reportlinker.com ... report is available in its catalogue: ... Market: Western Europe Market Size, Segment ... http://www.reportlinker.com/p0797078/Nutraceuticals-Product-Market-Western-Europe-Market-Size-Segment-And-Country-Analysis-And-Forecasts-2007-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Nutraceutical ...
Cached Medicine Technology:Nutraceuticals Product Market: Western Europe Market Size, Segment And Country Analysis And Forecasts (2007-2017) 2Nutraceuticals Product Market: Western Europe Market Size, Segment And Country Analysis And Forecasts (2007-2017) 3Nutraceuticals Product Market: Western Europe Market Size, Segment And Country Analysis And Forecasts (2007-2017) 4
(Date:8/28/2014)... 2014 Alpine, NJ resident Othon Mourkakos ... team, Zebras In Tiaras, to benefit the Immune Deficiency ... October 26, 2014 in Foley Square, New York. ... Primary immunodeficiency diseases (PI) are a group of more ... of the body’s immune system is missing or functions ...
(Date:8/28/2014)... CA (PRWEB) August 28, 2014 MarijuanaDoctors.com ... California physician, James Patel M.D. of Livermore, California. As ... best and most qualified physicians, and in accordance with ... our patients to Dr. Patel’s practice. , Initially finding ... a young age, Dr. Patel was shaped by his ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 MMAR Medical ... program is a chance for regular customers to enjoy ... without the need for a wholesale license. It’s a ... semi-professional athletic programs and others who regularly purchase medical ... , “Whether supporting your own active lifestyle or those ...
(Date:8/28/2014)... 28, 2014 The Pulmonica is a ... resonant, meditative sounds that can be felt vibrating in ... to use it – just taking long, slow, deep ... , Here are some examples of how to ... your eyes, relax, and maintain good posture. Try to ...
(Date:8/28/2014)... 28, 2014 Coveros, Inc., the ... that it has partnered with InfoZen on the ... start date of 2/4/2014 with U.S. Citizenship and ... (DHS) agency that oversees lawful immigration to the ... InfoZen will automate the integration and delivery of ...
Breaking Medicine News(10 mins):Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 2Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 3Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 4Health News:MMAR Medical Announces Customer Membership Program 2Health News:Ever Thought of Meditating With a Harmonica; Harmonica Techs, Inventors of the Pulmonica® Pulmonary Harmonica®, Present Tips on How to Relax with Soothing Sounds 2Health News:Coveros Partners with InfoZen on USCIS Transformation Integration Award 2
... and its partner Hyderabad-based Biological E. Ltd. announced ... a pediatric phase II clinical trial for Intercell’s ... ,The randomized and controlled study aims to demonstrate ... vaccine compared to a locally produced mouse-brain Japanese ...
... the U.S. population. Nearly one-third of affected people have ... do not work well. Those who suffer from it ... biofeedback treatment can successfully retrain muscles. ,The biofeedback ... and exercise or another treatment (sham) that included muscle ...
... Responding to calls for a fair distribution of bird ... to create a global stockpile of vaccines// for developing ... great importance in the fight against avian influenza, WHO ... The Jakarta Post Thursday. ,Chan met President ...
... and Wales have been accused of being institutionally racist. ... although services are pioneers in moving towards equity, they ... challenges of a multi-cultural society. ,The "Count ... Commission, makes grim reading for people of African and ...
... during a recent influenza B epidemic in Japan showed ... drugs//, according to a study. ,Two antiviral ... drugs known as neuraminidase inhibitors, have been effective against ... evidence of the emergence of oseltamivir-resistant type A viruses, ...
... ruling in Alberta empowers pharmacists to prescribe medicines to ... will be allowed to take a decision on the ... or prescriptions given by doctors. ,Though this ... about the ability of the pharmacists to diagnose medical ...
Cached Medicine News:Health News:Biofeedback Treats One Type Of Chronic Constipation 2Health News:Biofeedback Treats One Type Of Chronic Constipation 3Health News:Chances of Tackling Racism in Mental Health Care is Still Remote 2Health News:Study Suggests Some Drug Resistance to Influenza B Medications 2
Full Handle Laseredge Implant Blade Knife, 5.2 mm angled bevel up. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, angled double bevel. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Stab Blade Knife, 22.5 blade. Blade tip dimension: 10.7 mm x 1.8 mm x 4.2 mm....
18 gauge straight. Fine tip. Lightweight design offers precise hemostasis. Pencil design minimizes tissue trauma and induced astigmatism. Knurled handle provides a sure grip and better manipulation....
Medicine Products: